skip to main content

Sair
Identificação

Idioma:

Pressure group urges rosuvastatin recall

Ault, Alicia

The Lancet (British edition), 2004-03, Vol.363 (9412), p.871-871 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Pressure group urges rosuvastatin recall
Autor: Ault, Alicia
Assuntos: Adult ; Advisory Committees ; Drug and Narcotic Control ; Drugs ; Female ; Fluorobenzenes - adverse effects ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Kidneys ; Male ; Marketing ; Middle Aged ; Petitions ; Product recalls ; Pyrimidines - adverse effects ; Renal Insufficiency - chemically induced ; Rhabdomyolysis - chemically induced ; Rosuvastatin Calcium ; Side effects ; Statins ; Sulfonamides - adverse effects ; United States ; United States Food and Drug Administration
É parte de: The Lancet (British edition), 2004-03, Vol.363 (9412), p.871-871
Descrição: Launched in September, 2003, in the USA, rosuvastatin has not been the blockbuster AstraZeneca hoped it would be. The company's estimates for the first full-year sales in the USA are US$62 million, with another $67 million from the UK, the Netherlands, and Canada. But in January, rosuvastatin had only about 5% of the US statin market share.
Editor: England: Elsevier Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Buscando em bases de dados remotas. Favor aguardar.

Buscando por
emscope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
Mostrar o que foi encontrado até o momento